Coverage of the 2017 Conference on Retroviruses and Opportunistic Infections

HIVandHepatitis.com coverage of the 2017 Conference on Retroviruses and Opportunistic infections (CROI 2017), February 13-16, 2017, in Seattle.

Full coverage listing by topic

CROI website

4/16/17

CROI 2016: Advances in Hepatitis C Research [VIDEO]

Interferon-free therapy can now cure most patients with chronic hepatitis C, but challenges still remain, including persistent liver damage and cancer risk and HCV reinfection after successful treatment. A panel of hepatitis C experts discuss research presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2016) and related news with HIVandHepatitis.com editor Liz Highleyman in this IFARA video update.

Read more:

CROI 2016: Studies Probe Retention in Care for HIV+ Women Who Start ART During Pregnancy

Engaging lay counselors to provide a combination package of evidence-based interventions in Nyanza, Kenya, and addressing partner disclosure, as well as pre-treatment education about the benefits of antiretroviral therapy (ART) for maternal and child health in Malawi’s Option B+ program improved retention in care and reduced loss to follow-up of mothers with HIV and their infants, studies presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2016) show.

Read more:

CROI 2016: Long-Acting MK-8591 Could Be Future Option for HIV Treatment and Prevention

Merck's MK-8591, an investigational antiretroviral agent that maintains drug levels that are able to inhibit HIV up to 6 months after dosing could represent a "paradigm shift" in HIV therapy and prophylaxis, according to research presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2016) in Boston.

Read more:

CROI 2016: HIV/HBV Coinfection Linked to Worse Immune Recovery and Death

HIV-positive people with hepatitis B virus (HBV) coinfection had impaired CD4 cell recovery after starting antiretroviral (ART) and a higher risk of death than those without hepatitis B, but use of ART regimens containing tenofovir significantly reduced mortality, according to a study presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2016)in Boston.

Read more:

CROI 2016: Partner Notification of HIV Status Is Feasible and Effective In African Settings

Partner notification programs, offering testing to the sexual partners of people newly diagnosed with HIV, have rarely been implemented in African countries, but can be highly effective there, studies presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2016)show. A randomized study in Kenya found that partner notification services were able to test 42% of partners mentioned, increasing testing rates 4-fold.

Read more:

CROI 2016: Hepatitis C [VIDEO]

New interferon-free treatment for hepatitis C virus (HCV) has brought about a revolution in treatment, but challenges still remain -- among them too few people with HCV being diagnosed and the high cost of the new drugs -- before the mission can be declared a success. A panel of hepatitis C experts discuss research presented at the recent 2015 Conference on Retroviruses and Opportunistic Infections(CROI) in Seattle with HIVandHepatitis.com editor Liz Highleyman in this IFARA video.

Read more:

CROI 2016: VRC01 Antibody Delays But Does Not Prevent HIV Rebound After ART Interruption

VRC01, a broadly neutralizing antibody targeting HIV's CD4 binding site, was able to modestly delay the return of viral replication following interruption of antiviral therapy (ART), according to a study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016)last month in Boston. VRC01 did not maintain viral suppression on its own, but it may play a role in combination therapy for HIV treatment or a functional cure.

Read more: